Mitochondrial oxidative stress has been reported as the result of respiratory complex anomalies, genetic defects, or insufficient oxygen or glucose supply. Although Ca(2+) has no direct effect on respiratory chain function or oxidation/reduction process, mitochondrial Ca(2+) overload can lead to reactive oxygen species (ROS) increase. Even though Ca(2+) is well known for its role as crucial second messenger in modulating many cellular physiological functions, Ca(2+) overload is detrimental to mitochondrial function and may present as an important cause of mitochondrial ROS generation. Possible mechanisms include Ca(2+) stimulated increase of metabolic rate, Ca(2+) stimulated nitric oxide production, Ca(2+) induced cytochrome c dissociation, Ca(2+) induced cardiolipin peroxidation, Ca(2+) induced mitochondrial permeability transition pore opening with release of cytochrome c and GSH-antioxidative enzymes, and Ca(2+)-calmodulin dependent protein kinases activation. Different mechanisms may exist under different mitochondrial preparations (isolated mitochondria vs. mitochondria in intact cells), tissue sources, animal species, or inhibitors used. Furthermore, mitochondrial ROS rise can modulate Ca(2+) dynamics and augment Ca(2+) surge. The reciprocal interactions between Ca(2+) induced ROS increase and ROS modulated Ca(2+) upsurge may cause a feedforward, self-amplified loop createing cellular damage far beyond direct Ca(2+) induced damage.

The cause of Parkinson's disease (PD) is unknown, but reduced activity of complex I of the electron-transport chain has been implicated in the pathogenesis of both mitochondrial permeability transition pore-induced Parkinsonism and idiopathic PD. We developed a novel model of PD in which chronic, systemic infusion of rotenone, a complex-I inhibitor, selectively kills dopaminergic nerve terminals and causes retrograde degeneration of substantia nigra neurons over a period of months. The distribution of dopaminergic pathology replicates that seen in PD, and the slow time course of neurodegeneration mimics PD more accurately than current models. Our model should enhance our understanding of neurodegeneration in PD. Metabolic impairment depletes ATP, depresses Na+/K(+)-ATPase activity, and causes graded neuronal depolarization. This relieves the voltage-dependent Mg2+ block of the N-methyl-D-aspartate (NMDA) subtype of the glutamate receptor, which is highly permeable to Ca2+. Consequently, innocuous levels of glutamate become lethal via secondary excitotoxicity. Mitochondrial impairment also disrupts cellular Ca2+ homoeostasis. Moreover, the facilitation of NMDA-receptor function leads to further mitochondrial dysfunction. To a large part, this occurs because Ca2+ entering neurons through NMDA receptors has 'privileged' access to mitochondria, where it causes free-radical production and mitochondrial depolarization. Thus there may be a feed-forward cycle wherein mitochondrial dysfunction causes NMDA-receptor activation, which leads to further mitochondrial impairment. In this scenario, NMDA-receptor antagonists may be neuroprotective.

concentrations (30-500 mM) inhibited this activity. Acute exposure of control cf-EPC to 100 mM MGO increased basal cytoplasmic Ca 2þ and this was followed by an increased production of mitochondrial superoxide. These new data suggest that MGO whose production is increased shortly after the onset of hyperglycemia is inducing cf-EPC demise by mechanisms that involve perturbations in intracellular calcium homeostasis and increased production of mitochondrial superoxide. Overexpression of glyoxalase 1 minimizes the effects of MGO.

No abstract

No abstract